Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb
Fig.1: Coomassie staining of SDS PAGE gel loaded with 5ug of Anti-IL-17A (Ixekizumab biosimilar) mAb (Abeomics cat# 12-2002)
Roll over image to zoom in
Shipping Info:
Order now and get it on Tuesday July 15, 2025
Same day delivery FREE on San Diego area orders placed by 1.00 PM
| Amount : | 100 µg |
| Isotype : | IgG4 |
| Purification : | Purified from cell culture supernatant by affinity chromatography |
| Storage condition : | Store at -20°C to -80°C (Avoid repeated freezing and thawing). |
Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils, lymphocytes, macrophages, monocytes, natural killer (NK) cells, and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway, leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.
ELISA 1:5000-10000, FACS 1:100
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
